Health Dictionary Find a Doctor

Epilepsy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

overview

Medical Therapy

Pharmacologic medical therapies for epilepsy is anti-seizure drugs such as:

Drugs that affect voltage-dependent Na+ channels

Drugs that affect Ca currents

Drugs that affect GABA activity

Drugs that affect glutamate receptor

Drugs with multiple mechanisms of action

Drugs with other mechanisms of action

  • Brivaracetam
    • It can be used for treatment of focal-onset seizures and generalized epilepsy.[47][48]
    • The initial dosage is 50 mg twice daily.[49]
    • The most common side effects are irritability, anxiety, insomnia and depression.[50]
  • Gabapentin
    • It can be used for treatment of refractory focal seizures.[51]
    • The initial dosage is 300 mg three times daily.
    • The maximum dosage is 2400 mg/day.[52]
    • The most common side effects are sedation, dizziness, ataxia and weight gain.[53]
  • Levetiracetam
    • It can be used for adjunctive treatment of focal-onset seizures, myoclonic seizures in patients older than 12 y/o with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients older than six y/o with idiopathic generalized epilepsy.[54][55][56]
    • The initial dosage is 500 mg twice daily.
    • The maximum dosage is 4000 mg daily.[57]
    • The most common side effects are fatigue, drowsiness, dizziness, and upper respiratory tract infection.[58]
  • Pregabalin
    • It can be used for adjunctive therapy for focal seizures.[59]
    • The initial dosage is 150 mg daily in either two or three divided doses.[60]
    • The most common side effects are dizziness, gait abnormalities and drowsiness.[61]

References

  1. ↑ Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Bazil CW (November 2008). “Cross-sensitivity of skin rashes with antiepileptic drug use”. Neurology. 71 (19): 1527–34. doi:10.1212/01.wnl.0000334295.50403.4c. PMIDΒ 18981374.
  2. ↑ Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG (May 1974). “Carbamazepine for epilepsy. A controlled prospective evaluation”. Neurology. 24 (5): 401–10. PMIDΒ 4207990.
  3. ↑ Chang XC, Yuan H, Wang Y, Xu HQ, Hong WK, Zheng RY (October 2017). “Eslicarbazepine acetate add-on for drug-resistant partial epilepsy”. Cochrane Database Syst Rev. 10: CD008907. doi:10.1002/14651858.CD008907.pub3. PMIDΒ 29067682.
  4. ↑ Almeida L, Minciu I, Nunes T, Butoianu N, FalcΓ£o A, Magureanu SA, Soares-da-Silva P (August 2008). “Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy”. J Clin Pharmacol. 48 (8): 966–77. doi:10.1177/0091270008319706. PMIDΒ 18508949.
  5. ↑ Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, Kowacs PA, Hong SB, Cheng H, Blum D, Nunes T, Soares-da-Silva P (February 2015). “Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial”. Epilepsia. 56 (2): 244–53. doi:10.1111/epi.12894. PMCΒ 4354260. PMIDΒ 25528898.
  6. ↑ Perucca E, Yasothan U, Clincke G, Kirkpatrick P (December 2008). “Lacosamide”. Nat Rev Drug Discov. 7 (12): 973–4. doi:10.1038/nrd2764. PMIDΒ 19043448.
  7. ↑ Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD, HalΓ‘sz P, KΓ€lviΓ€inen R, Mazurkiewicz-BeldziΕ„ska M, Rosenow F, Doty P, Hebert D, Sullivan T (July 2007). “Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures”. Epilepsia. 48 (7): 1308–17. doi:10.1111/j.1528-1167.2007.01188.x. PMIDΒ 17635557.
  8. ↑ Perucca E, Yasothan U, Clincke G, Kirkpatrick P (December 2008). “Lacosamide”. Nat Rev Drug Discov. 7 (12): 973–4. doi:10.1038/nrd2764. PMIDΒ 19043448.
  9. ↑ French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA (April 2004). “Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society”. Neurology. 62 (8): 1252–60. PMIDΒ 15111659.
  10. ↑ Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR, Morrell MJ (September 2004). “Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy”. Neurology. 63 (6): 1022–6. PMIDΒ 15452293.
  11. ↑ Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Bazil CW (November 2008). “Cross-sensitivity of skin rashes with antiepileptic drug use”. Neurology. 71 (19): 1527–34. doi:10.1212/01.wnl.0000334295.50403.4c. PMIDΒ 18981374.
  12. ↑ Koch MW, Polman SK (October 2009). “Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures”. Cochrane Database Syst Rev (4): CD006453. doi:10.1002/14651858.CD006453.pub2. PMIDΒ 19821367.
  13. ↑ Kim DW, Gu N, Jang IJ, Chu K, Yu KS, Cho JY, Yoon SH, Kim HS, Oh J, Lee SK (January 2012). “Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy”. Epilepsia. 53 (1): e9–12. doi:10.1111/j.1528-1167.2011.03318.x. PMIDΒ 22091603.
  14. ↑ Buggy Y, Layton D, Fogg C, Shakir SA (May 2010). “Safety profile of oxcarbazepine: results from a prescription-event monitoring study”. Epilepsia. 51 (5): 818–29. doi:10.1111/j.1528-1167.2009.02489.x. PMIDΒ 20132298.
  15. ↑ Yaari Y, Selzer ME, Pincus JH (August 1986). “Phenytoin: mechanisms of its anticonvulsant action”. Ann. Neurol. 20 (2): 171–84. doi:10.1002/ana.410200202. PMIDΒ 2428283.
  16. ↑ Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT (November 2014). “Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing”. Clin. Pharmacol. Ther. 96 (5): 542–8. doi:10.1038/clpt.2014.159. PMIDΒ 25099164.
  17. ↑ Iivanainen M, Savolainen H (1983). “Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy”. Acta Neurol. Scand., Suppl. 97: 49–67. PMIDΒ 6424397.
  18. ↑ Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S (May 2008). “Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome”. Neurology. 70 (21): 1950–8. doi:10.1212/01.wnl.0000303813.95800.0d. PMIDΒ 18401024.
  19. ↑ Marchand M, Fuseau E, Critchley DJ (February 2010). “Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation”. J Pharmacokinet Pharmacodyn. 37 (1): 99–118. doi:10.1007/s10928-009-9146-4. PMIDΒ 20084538.
  20. ↑ Wheless JW, Vazquez B (January 2010). “Rufinamide: a novel broad-spectrum antiepileptic drug”. Epilepsy Curr. 10 (1): 1–6. doi:10.1111/j.1535-7511.2009.01336.x. PMCΒ 2812713. PMIDΒ 20126329.
  21. ↑ Guerrini R, Rosati A, Segieth J, Pellacani S, Bradshaw K, Giorgi L (August 2013). “A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy”. Epilepsia. 54 (8): 1473–80. doi:10.1111/epi.12233. PMIDΒ 23837461.
  22. ↑ Leppik IE (December 2004). “Zonisamide: chemistry, mechanism of action, and pharmacokinetics”. Seizure. 13 Suppl 1: S5–9, discussion S10. doi:10.1016/j.seizure.2004.04.016. PMIDΒ 15511691.
  23. ↑ Park SP, Hwang YH, Lee HW, Suh CK, Kwon SH, Lee BI (January 2008). “Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients”. Epilepsy Behav. 12 (1): 102–8. doi:10.1016/j.yebeh.2007.08.002. PMIDΒ 17945539.
  24. ↑ Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC (March 2010). “Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy”. N. Engl. J. Med. 362 (9): 790–9. doi:10.1056/NEJMoa0902014. PMCΒ 2924476. PMIDΒ 20200383.
  25. ↑ Uzun S, Kozumplik O, JakovljeviΔ‡ M, SediΔ‡ B (March 2010). “Side effects of treatment with benzodiazepines”. Psychiatr Danub. 22 (1): 90–3. PMIDΒ 20305598.
  26. ↑ “apps.who.int” (PDF).
  27. ↑ Camfield CS, Chaplin S, Doyle AB, Shapiro SH, Cummings C, Camfield PR (September 1979). “Side effects of phenobarbital in toddlers; behavioral and cognitive aspects”. J. Pediatr. 95 (3): 361–5. PMIDΒ 381616.
  28. ↑ French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA (April 2004). “Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society”. Neurology. 62 (8): 1252–60. PMIDΒ 15111659.
  29. ↑ Pulman J, Marson AG, Hutton JL, French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA (May 2012). “Tiagabine add-on for drug-resistant partial epilepsy”. Cochrane Database Syst Rev. 62 (5): CD001908. doi:10.1002/14651858.CD001908.pub2. PMCΒ 4058679. PMIDΒ 22592677.
  30. ↑ Hemming K, Maguire MJ, Hutton JL, Marson AG (January 2013). “Vigabatrin for refractory partial epilepsy”. Cochrane Database Syst Rev (1): CD007302. doi:10.1002/14651858.CD007302.pub2. PMIDΒ 23440814.
  31. ↑ “Vigabatrin (Sabril) for epilepsy”. Med Lett Drugs Ther. 52 (1332): 14–6, quiz 17. February 2010. PMIDΒ 20208475.
  32. ↑ Chadwick D (July 1999). “Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group”. Lancet. 354 (9172): 13–9. PMIDΒ 10406359.
  33. ↑ “Drugs@FDA: FDA Approved Drug Products”.
  34. ↑ Coyle H, Clough P, Cooper P, Mohanraj R (December 2014). “Clinical experience with perampanel: focus on psychiatric adverse effects”. Epilepsy Behav. 41: 193–6. doi:10.1016/j.yebeh.2014.09.072. PMIDΒ 25461214.
  35. ↑ French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA (August 2012). “Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304”. Neurology. 79 (6): 589–96. doi:10.1212/WNL.0b013e3182635735. PMCΒ 3413761. PMIDΒ 22843280.
  36. ↑ Bourgeois BF (1994). “Felbamate in the treatment of partial-onset seizures”. Epilepsia. 35 Suppl 5: S58–61. PMIDΒ 8039474.
  37. ↑ O’Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S (May 1996). “Felbamate-associated fatal acute hepatic necrosis”. Neurology. 46 (5): 1457–9. PMIDΒ 8628501.
  38. ↑ Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG (February 2014). “Topiramate add-on for drug-resistant partial epilepsy”. Cochrane Database Syst Rev (2): CD001417. doi:10.1002/14651858.CD001417.pub3. PMIDΒ 24570033.
  39. ↑ Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, Mao L, Wiegand F, Hulihan J (October 2010). “Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial”. Epilepsia. 51 (10): 1970–7. doi:10.1111/j.1528-1167.2010.02670.x. PMIDΒ 20633037.
  40. ↑ Majkowski J, Neto W, Wapenaar R, Van Oene J (May 2005). “Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine”. Epilepsia. 46 (5): 648–53. doi:10.1111/j.1528-1167.2005.35904.x. PMIDΒ 15857429.
  41. ↑ Loiseau P (1984). “Rational use of valproate: indications and drug regimen in epilepsy”. Epilepsia. 25 Suppl 1: S65–72. PMIDΒ 6425050.
  42. ↑ Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS (January 2001). “Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy”. Neurology. 56 (2): 172–7. PMIDΒ 11160951.
  43. ↑ Endo A, Fujita Y, Fuchigami T, Takahashi S, Mugishima H (April 2010). “Fanconi syndrome caused by valproic acid”. Pediatr. Neurol. 42 (4): 287–90. doi:10.1016/j.pediatrneurol.2009.12.003. PMIDΒ 20304335.
  44. ↑ Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, KΓΆnig S (July 2006). “Valproate-associated coagulopathies are frequent and variable in children”. Epilepsia. 47 (7): 1136–43. doi:10.1111/j.1528-1167.2006.00587.x. PMIDΒ 16886976.
  45. ↑ Sahota P, Prabhakar S, Kharbanda PS, Bhansali A, Jain V, Das CP, Modi M (December 2008). “Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study”. Epilepsia. 49 (12): 2069–77. doi:10.1111/j.1528-1167.2008.01676.x. PMIDΒ 18503558.
  46. ↑ Aggarwal A, Rastogi N, Mittal H, Chillar N, Patil R (September 2011). “Thyroid hormone levels in children receiving carbamazepine or valproate”. Pediatr. Neurol. 45 (3): 159–62. doi:10.1016/j.pediatrneurol.2011.04.005. PMIDΒ 21824562.
  47. ↑ Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P (December 2015). “A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures”. Epilepsia. 56 (12): 1890–8. doi:10.1111/epi.13212. PMIDΒ 26471380.
  48. ↑ Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P (December 2015). “A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures”. Epilepsia. 56 (12): 1890–8. doi:10.1111/epi.13212. PMIDΒ 26471380.
  49. ↑ “Drugs@FDA: FDA Approved Drug Products”.
  50. ↑ Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P (December 2015). “A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures”. Epilepsia. 56 (12): 1890–8. doi:10.1111/epi.13212. PMIDΒ 26471380.
  51. ↑ French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA (April 2004). “Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society”. Neurology. 62 (8): 1261–73. PMIDΒ 15111660.
  52. ↑ Al-Bachari S, Pulman J, Hutton JL, Marson AG (July 2013). “Gabapentin add-on for drug-resistant partial epilepsy”. Cochrane Database Syst Rev (7): CD001415. doi:10.1002/14651858.CD001415.pub2. PMIDΒ 23888424.
  53. ↑ Smith RV, Havens JR, Walsh SL (July 2016). “Gabapentin misuse, abuse and diversion: a systematic review”. Addiction. 111 (7): 1160–74. doi:10.1111/add.13324. PMCΒ 5573873. PMIDΒ 27265421.
  54. ↑ Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U (October 2007). “Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy”. Neurology. 69 (18): 1751–60. doi:10.1212/01.wnl.0000268699.34614.d3. PMIDΒ 17625106.
  55. ↑ Mbizvo GK, Dixon P, Hutton JL, Marson AG (September 2012). “Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review”. Cochrane Database Syst Rev (9): CD001901. doi:10.1002/14651858.CD001901.pub2. PMIDΒ 22972056.
  56. ↑ Delanty N, Jones J, Tonner F (January 2012). “Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study”. Epilepsia. 53 (1): 111–9. doi:10.1111/j.1528-1167.2011.03300.x. PMIDΒ 22050371.
  57. ↑ Betts T, Waegemans T, Crawford P (March 2000). “A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy”. Seizure. 9 (2): 80–7. doi:10.1053/seiz.2000.0380. PMIDΒ 10845730.
  58. ↑ Delanty N, Jones J, Tonner F (January 2012). “Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study”. Epilepsia. 53 (1): 111–9. doi:10.1111/j.1528-1167.2011.03300.x. PMIDΒ 22050371.
  59. ↑ Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S (January 2004). “Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures”. Epilepsia. 45 (1): 20–7. PMIDΒ 14692903.
  60. ↑ Warner G, Figgitt DP (2005). “Pregabalin: as adjunctive treatment of partial seizures”. CNS Drugs. 19 (3): 265–72, discussion 273–4. doi:10.2165/00023210-200519030-00007. PMIDΒ 15740180.
  61. ↑ Zaccara G, Gangemi P, Perucca P, Specchio L (April 2011). “The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials”. Epilepsia. 52 (4): 826–36. doi:10.1111/j.1528-1167.2010.02966.x. PMIDΒ 21320112.

Template:WH Template:WS

Β© 2026 MyEClinic – IFTM Institut fΓΌr Telematik in der Medizin GmbH